ARCT Arcturus Therapeutics Holdings Inc

$ARCT With Lunar2.0, Arcturus can now expand into other therapeutic targets such as PKU and Gout, and potentially other liver indications as well. Hence, I strongly believe market is currently very underestimating the potential of Lunar2.0. Imaging making a different mRNA construct for other liver diseases and using Lunar2.0 which is a highly effective delivery system that provides a 38 fold increase in potency for the target liver enzyme, it could be a Plug and Play model system going forward. The vehicle stays the same, ie the LNP, the cargo changes, example for OTC deficiency, can load mRNA that codes for OTC enzyme, for PKU, switch the cargo to mRNA that codes for PAH enzyme and for Gout, switch it to an mRNA sequence that targets uric acid clearance. Just my own thinking….very bullish….

$ARCT Moderna at 80 Billion MC. His little brother (or sister) at 400 Million. But one day she'll grow up, too. She's already very smart.😎😀

$ARCT Take a few minutes and research myNEO Therapeutics for yourself. For those not paying attention, this is the company Arcturus just acquired. Seems their main focus is in cancer research. Even Sumdumphuq can see how bright the future is for Arcturus.

$ARCT well, not the blowout news we were hoping for but good long term news. Lunar 2.0, positive data on otc and good plans moving forward. We should move up from here. It’s the makings of a good, solid company for years to come. Soon our market cap will be measured in the billions, not hundreds of millions.

$ARCT OTC Phase 2 proves the concept works. Switching to LUNAR 2.0 with 38x higher expression makes sense for lower doses and a better drug. Delay sucks, but it’s the right move long term. Buying the dip.

$ARCT Upcoming catalysts for ARCT: Out-licensing the Seasonal Flu Phase 2-ready sa-mRNA quadrivalent vaccine , partnering the BARDA backed pandemic influenza asset, securing a regional commercial distributor for KOSTAIVE in Europe and the UK, Advancing KOSTAIVE toward U.S. BLA filing

$ARCT nobody knows nothjng. just funds hedging their positions.. volume on both puts and calls is way too low. if someone actually knew something youd be seeing 20,000+ volume on puts or calls.

$ARCT Posted this today in the PACB-Thread: Genetics is currently the “crème de la crème” of medical research. Only the most renowned research institutes, researchers, and university hospitals worldwide are working in this field. As mentioned in some of the posts here, examples are frequently cited of those who work with or use PACB’s systems. Widespread adoption is only a matter of time, as genetics will increasingly provide answers to the unknowns surrounding health and disease. As for my investment here, I’ll be patient and won’t let the ups and downs throw me off. Why I post it also here? Because Arcturus will deliver/provides the practical application. So let's stay patient and wait until the general public and the big players get on board here, too. Thanks to the users here who provide regular updates.

$ARCT wall st analysts have just upgraded Arct from buy to strong buy. I would expect more upgrades to come.

$ARCT Yesterday, the presentation highlighted very positive results for 810, therapy for OTC deficiency. In the latest set of results, ammonia and glutamine levels are reduced and within normal range. This implies that 810 works and demonstrated highly encouraging efficacy and safety profiles. The huge surprise is the unveiling of Lunar2.0, its next generation mRNA delivery platform. This is a massive structural upgraded platform that future iterations can likely offer far lower, safer and less frequent dosing cycles. The fact that the FDA gives them the green light to immediately integrate their next-gen candidate ARCT2601 into the ongoing Phase 2 study is proof of the confidence and promise in the delivery system.

$ARCT Feeling better than ever about this stock. It will just take a little longer to get there. But when it does, it’s going to explode.

$ARCT new article on seeking alpha. Says that tomorrow is going to move the stock significantly. Hence the large volume of options.

$ARCT BioNTech $BNTX fell after its experimental mRNA cancer drug BNT113 missed key endpoint. Personally I believe Arcturus has much better platforms and technologies and it can develop better oncology therapies in the future….. So far I think Moderna $MRNA is racing ahead….

$ARCT The more I look into Arcturus and think about it, the more I’m convinced that this company—which is still relatively unknown at this stage but is making great strides with its mRNA approach—has a bright future ahead, unless a major player acquires it.

$ARCT It will not be surprised if a partnership with Biontech come soon. They are left behind with competition. Also Gout is a good indication for sure revenues if gene editing become available broadly. There is no Gene at all. Very smart.

$ARCT I was buying heavily when this stock was below 6. See my post history. This is another great time to buy. I bought heavily again.

$ARCT Until recently, Cathie Wood's AKRG ETF held about 2.7 million shares of Artc.. But suddenly it jumped to about 5.6 million shares. Even looking at the past data on the x(Twitter) Ark Invest Tracker, I couldn't find when this large-scale purchase was madeAnyway, if this isn't a typo, that's very surprising. No such large-volume buy order has occurred in the market; did they acquire the shares through over-the-counter trading..I simply don't know. If you know anything about this, I would appreciate it if you could share

$ARCT "Under the deal, Novartis will gain exclusive rights to Abogen's experimental ​drug, ABO2203, and options to license other therapies based on Abogen's RNA technology. Abogen will receive $575 million upfront with the potential to earn an additional $7.2 billion if the drug advances through development and wins regulatory approval." https://www.reuters.com/legal/litigation/novartis-strikes-about-78-billion-mrna-deal-with-chinas-abogen-2026-10-02/

$ARCT two more months, maybe less, and we have a go decision into phase 3 regarding cf. plus partnership coming this year i believe.

$ARCT I thought there might be an A.I component to this presentation. Joe eluded to announcing their strategy around A.I in one of the talks last month and he sounded like it was going to be a big focus. I think he said something like he’s been surprised how impactful A.I has been in their business.